Manhattan Pharmaceuticals Inc.
Manhattan Pharmaceuticals Inc. is listed today as TG Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2011 | $11 M | No. 1 | $10 to $50 million | equity, options | SEC | |
| Mar 2010 | $3 M | Issued in a merger or acquisition | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company TG Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: License $9.36 million (2%), Royalty $5.62 million (1%), Other Revenue $3.59 million (1%), License Revenue $150,000 (0%).
Annual report (SEC XBRL) · Dec 2025
Manhattan Pharmaceuticals Inc. had no revenue when it filed its newest notice of a funding round (Mar 2012).
SEC Form D (revenue range) · Mar 2012
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Mar 2012
Products and services#
No products or services of Manhattan Pharmaceuticals Inc. are on record.
Investors#
3 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Michael S. Weiss | Person | not stated | not stated | Held Series A preferred stock, 10% owner, director (Form 3, 2012) | SEC Form 3 |
| Opus Point Partners, LLC | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| Sean A. Power | Person | not stated | not stated | Held Series A preferred stock (Form 3, 2012) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 0 investors.
Largest shareholders today
Institutions holding TG Therapeutics, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$1.3 B14.98%
- State Street Corp$474 M5.62%
- Vanguard Portfolio Management LLC$440 M5.21%
- Vanguard Capital Management LLC$349 M4.14%
- Geode Capital Management, LLC$207 M2.45%
- Two Sigma Investments, LP$188 M2.23%
- D. E. Shaw & Co., Inc.$183 M2.17%
- Congress Asset Management Co$145 M1.72%
- Soleus Capital Management, L.P.$143 M1.69%
- Goldman Sachs Group Inc$139 M1.65%
- Barclays PLC$135 M1.60%
- Clearbridge Investments, LLC$119 M1.42%
- Frontier Capital Management Co LLC$113 M1.34%
- First Trust Advisors LP$107 M1.27%
- Price T Rowe Associates Inc /MD/$107 M1.26%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Michael Weiss | Executive officer | Mar 2012 |
| Sean Power | Executive officer | Mar 2012 |
| Michael McGuinness | Executive officer | Mar 2010 |
| Michael Weiss | Director | Mar 2012 |
| Neil Herskowitz | Director | Mar 2012 |
| Douglas Abel | Director | Mar 2010 |
| Richard Steinhart | Director | Mar 2010 |
| Timothy McInerney | Director | Mar 2010 |
About
A commercial stage biopharmaceutical company.
Went public since 2013. Its SEC number is that of a company listed on a stock exchange.